Zipalertinib Matching-placebo
Phase 3
Taiho Oncology, Inc.Zipalertinib Matching-placebo is one of 5 therapeutic programs targeting NSCLC, Stage IB-IIIA. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
4 competitors in NSCLC, Stage IB-IIIA
#DrugCompanyPhaseTrials
1Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Paraplatin
AAvyxa
Phase 3
Alimta
GGynecologic Oncology Group
Phase 3
TAS6417
Taiho Oncology, Inc.Phase 3
Zipalertinib Matching-placebo
Taiho Oncology, Inc.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]
- Company